The two derivatives represent rational computationally designed compounds prioritized for further biological investigation and hit optimization targeted for future development of chalcone based derivatives as new anti-breast cancer therapies with ERα inhibitor activity and better side effect profiles compared to tamoxifen. The gene discussed is ESR1; the disease is breast cancer.